AIMS: Coronary artery occlusion resulting in ischaemia/reperfusion (I/R) injury is a major cause of mortality in the western world. Circulating natural IgM has been shown to play a significant role in reperfusion injury, leading to the notion of a pathogenic response against self by the innate immune system. A specific self-antigen (non-muscle myosin heavy chain II) was recently identified as the major target of pathogenic natural IgM. Therefore, we hypothesized that a synthetic peptide mimetope (N2) or monoclonal antibodies directed against the self-antigen would prevent specific IgM binding to the self-antigen and reduce reperfusion injury in the heart. METHODS AND RESULTS: We find that treatment with N2 peptide reduces infarct size by 47% and serum cardiac troponin-I levels by 69% following 1 h ischaemia and 24 h reperfusion. N2 peptide or an anti-N2 F(ab')(2) (21G6) is also effective at preventing IgM and complement deposition. Additionally, N2 peptide treatment significantly reduces monocyte and neutrophil infiltration at 24 h and collagen deposition at 5 days. Finally, we show that human IgM (hIgM) also includes specificity for the highly conserved self-antigen and that myocardial injury in antibody-deficient mice reconstituted with hIgM is blocked by treatment with N2 peptide or 21G6 F(ab')(2). CONCLUSION: The findings in this study identify potential therapeutics [i.e. N2 peptide or 21G6 F(ab')(2)] that prevent specific IgM binding to ischaemic antigens in the heart, resulting in a significant reduction in cardiac I/R injury.
AIMS: Coronary artery occlusion resulting in ischaemia/reperfusion (I/R) injury is a major cause of mortality in the western world. Circulating natural IgM has been shown to play a significant role in reperfusion injury, leading to the notion of a pathogenic response against self by the innate immune system. A specific self-antigen (non-muscle myosin heavy chain II) was recently identified as the major target of pathogenic natural IgM. Therefore, we hypothesized that a synthetic peptide mimetope (N2) or monoclonal antibodies directed against the self-antigen would prevent specific IgM binding to the self-antigen and reduce reperfusion injury in the heart. METHODS AND RESULTS: We find that treatment with N2 peptide reduces infarct size by 47% and serum cardiac troponin-I levels by 69% following 1 h ischaemia and 24 h reperfusion. N2 peptide or an anti-N2 F(ab')(2) (21G6) is also effective at preventing IgM and complement deposition. Additionally, N2 peptide treatment significantly reduces monocyte and neutrophil infiltration at 24 h and collagen deposition at 5 days. Finally, we show that human IgM (hIgM) also includes specificity for the highly conserved self-antigen and that myocardial injury in antibody-deficientmice reconstituted with hIgM is blocked by treatment with N2 peptide or 21G6 F(ab')(2). CONCLUSION: The findings in this study identify potential therapeutics [i.e. N2 peptide or 21G6 F(ab')(2)] that prevent specific IgM binding to ischaemic antigens in the heart, resulting in a significant reduction in cardiac I/R injury.
Authors: Roberto Bolli; Lance Becker; Garrett Gross; Robert Mentzer; David Balshaw; David A Lathrop Journal: Circ Res Date: 2004-07-23 Impact factor: 17.367
Authors: Ming Zhang; William G Austen; Isaac Chiu; Elisabeth M Alicot; Rachel Hung; Minghe Ma; Nicola Verna; Min Xu; Herbert B Hechtman; Francis D Moore; Michael C Carroll Journal: Proc Natl Acad Sci U S A Date: 2004-03-03 Impact factor: 11.205
Authors: Donald Lloyd-Jones; Robert J Adams; Todd M Brown; Mercedes Carnethon; Shifan Dai; Giovanni De Simone; T Bruce Ferguson; Earl Ford; Karen Furie; Cathleen Gillespie; Alan Go; Kurt Greenlund; Nancy Haase; Susan Hailpern; P Michael Ho; Virginia Howard; Brett Kissela; Steven Kittner; Daniel Lackland; Lynda Lisabeth; Ariane Marelli; Mary M McDermott; James Meigs; Dariush Mozaffarian; Michael Mussolino; Graham Nichol; Véronique L Roger; Wayne Rosamond; Ralph Sacco; Paul Sorlie; Véronique L Roger; Randall Stafford; Thomas Thom; Sylvia Wasserthiel-Smoller; Nathan D Wong; Judith Wylie-Rosett Journal: Circulation Date: 2009-12-17 Impact factor: 29.690
Authors: David P Faxon; Raymond J Gibbons; Nicolas A F Chronos; Paul A Gurbel; Florence Sheehan Journal: J Am Coll Cardiol Date: 2002-10-02 Impact factor: 24.094
Authors: Russell R Reid; Sean Woodcock; Alexander Shimabukuro-Vornhagen; William G Austen; Lester Kobzik; Ming Zhang; Herbert B Hechtman; Francis D Moore; Michael C Carroll Journal: J Immunol Date: 2002-11-15 Impact factor: 5.422
Authors: Bart De Vries; Robert A Matthijsen; Tim G A M Wolfs; Annemarie A J H M Van Bijnen; Peter Heeringa; Wim A Buurman Journal: Transplantation Date: 2003-02-15 Impact factor: 4.939
Authors: Koichi Inagaki; Leon Chen; Fumiaki Ikeno; Felix H Lee; Ken-ichi Imahashi; Donna M Bouley; Mehrdad Rezaee; Paul G Yock; Elizabeth Murphy; Daria Mochly-Rosen Journal: Circulation Date: 2003-11-03 Impact factor: 29.690
Authors: Peter I Lobo; Amandeep Bajwa; Kailo H Schlegel; John Vengal; Sang J Lee; Liping Huang; Hong Ye; Umesh Deshmukh; Tong Wang; Hong Pei; Mark D Okusa Journal: J Immunol Date: 2012-01-18 Impact factor: 5.422
Authors: Carl Atkinson; Fei Qiao; Xiaofeng Yang; Peng Zhu; Nicholas Reaves; Liudmila Kulik; Martin Goddard; V Michael Holers; Stephen Tomlinson Journal: Circulation Date: 2015-02-17 Impact factor: 29.690
Authors: Sarah E Panzer; Nancy A Wilson; Bret M Verhoven; Ding Xiang; C Dustin Rubinstein; Robert R Redfield; Weixiong Zhong; Shannon R Reese Journal: Transplantation Date: 2018-03 Impact factor: 4.939
Authors: Lora G Bankova; Cecilia Lezcano; Gunnar Pejler; Richard L Stevens; George F Murphy; K Frank Austen; Michael F Gurish Journal: J Immunol Date: 2014-02-12 Impact factor: 5.422